Abstract:The ever-increasing antigenic diversity of the hemagglutinin (HA) of influenza A virus (IAV) poses a significant challenge for effective vaccine development. Notably, the matrix protein 2 (M2) is a highly conserved 97 amino acid long transmembrane tetrameric protein present in the envelope of IAV. More than 99 % of IAV strains circulating in American swine herds share the identical pandemic (pdm) isoform of M2, making it an ideal target antigen for a vaccine that could elicit broadly protective immunity. Here, using soluble nanoscale membrane assemblies termed nanodiscs (NDs), we designed this membrane mimetic nanostructures displaying full-length M2 in its natural transmembrane configuration (M2ND). Intramuscular (IM) immunization of swine with M2ND mixed with conventional emulsion adjuvant elicited M2-specific IgG antibodies in the serum that recognized influenza virions and M2-specific interferon-γ secreting cells present in the blood. Intranasal (IN) immunization with M2ND adjuvanted with a mycobacterial extract elicited M2-specific IgA in mucosal secretions that also recognized IAV. Immunization with an influenza whole inactivated virus (WIV) vaccine supplemented with a concurrent IM injection of M2ND mixed with an emulsion adjuvant increased the level of protective immunity afforded by the former against a challenge with an antigenically distinct H3N2 IAV, as exhibited by an enhanced elimination of virus from the lung. The lone IM administration of the M2ND vaccine mixed with an emulsion adjuvant provided measurable protection as evidenced by a >10-fold reduction or complete elimination of the challenge virus from the lung, but it did not diminish the viral load in nasal secretions nor the extent of pneumonia that ensued after the virus challenge. In contrast, an improved formulation of the M2ND vaccine that incorporated synthetic CpG oligodeoxynucleotides (CpG-ODN) in the nanostructures administered alone, via the IN and IM routes combined, provided a significant level of protective immunity against IAV as evidenced by a decreased viral load in both the upper and lower respiratory tracts and fully eliminated the occurrence of pneumonia in 89 % of the pigs immunized with this biologic. Notably, to be effective, the M2 protein must be displayed in the ND assemblies, as shown by the observation that simply mixing M2 with empty NDs incorporating CpG-ODN (eND-CpG-ODN) did not provide protective immunity. This novel M2-based vaccine offers great promise to help increase the breadth of protection afforded by conventional WIV vaccines against the diversity of IAV in circulation and, plausibly, as a broadly protective stand-alone biologic.

Universal Influenza Vaccine Based on the Extracellular Domain of M2 Protein

M2e-Based Universal Influenza A Vaccines

The Role of Matrix Protein 2 Ectodomain in the Development of Universal Influenza Vaccines

A Broad Protection Provided by Matrix Protein 2 (M2) of Avian Influenza Virus

Characterization of Immunity Induced by M2e of Influenza Virus.

M2e-based universal influenza vaccines: a historical overview and new approaches to development

Expression of Influenza M2e-NP Recombinant Fusion Protein in Escherichia coli BL21 (DE3) and Its Binding to Antibodies

Protection against homo and hetero-subtypic inﬂuenza A virus by optimized M2e DNA vaccine

An effective vaccine against influenza A virus based on the matrix protein 2 (M2)

Antigenicity and Immunogenicity of Influenza M2e Protein Fused with Intramolecular Adjuvant CRM 197

N-terminus of M2 Protein Could Induce Antibodies with Inhibitory Activity Against Influenza Virus Replication

[Construction, Expression and Immunogenicity Analysis of a Fusion Protein Containing M2e of Influenza A Virus Fused to a Modified Pseudomonas Aeruginosa Exotoxin A].

A Universal, Single-Component Multilayered Self-Assembling Protein Nanoparticle Vaccine Based on Extracellular Domains of Matrix Protein 2 Against Both Influenza A and B

M2e-specific Antibodies Protect Against Influenza PR8 Virus in an Isotype and Route Dependent Manner.

Monoclonal antibody recognizing SLLTEVET epitope of M2 protein potently inhibited the replication of influenza A viruses in MDCK cells.

Protection Against Influenza A Virus Challenge with M2e-Displaying Filamentous Escherichia Coli Phages

A Single-Component Multilayered Self-Assembling Protein Nanoparticle Vaccine Based on Extracellular Domains of Matrix Protein 2 against Both Influenza A and B

Self-Assembly M2e-Based Peptide Nanovaccine Confers Broad Protection Against Influenza Viruses

Monoclonal Antibodies Recognizing EVETPIRN Epitope of Influenza A Virus M2 Protein Could Protect Mice from Lethal Influenza A Virus Challenge

Monoclonal antibody against the universal M2 epitope of influenza A virus

Highly Conserved M2e and Hemagglutinin Epitope-Based Recombinant Proteins Induce Protection Against Influenza Virus Infection